Gastric Cancer

Updated: September 16, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

trastuzumab/deruxtecan

6.4 mg/kg intravenously every 3 weeks as a 21-day cycle
Continue until the disease is progressed
Dose Modifications
In the case of NSCLC or breast cancer
1st dose reduction- 4.4mg/kg
2nd dose reduction- 3.2mg/kg
Discontinue the treatment if further dose reduction is required
In the case of gastric cancer
In the case of NSCLC or breast cancer
1st dose reduction- 5.4mg/kg
2nd dose reduction- 4.4mg/kg
Discontinue the treatment if further dose reduction is required

trastuzumab deruxtecan

Dose Modifications
In the case of NSCLC or breast cancer
1st dose reduction- 4.4mg/kg
2nd dose reduction- 3.2mg/kg
Discontinue the treatment if further dose reduction is required
In the case of gastric cancer
In the case of NSCLC or breast cancer
1st dose reduction- 5.4mg/kg
2nd dose reduction- 4.4mg/kg
Discontinue the treatment if further dose reduction is required:

6.4 mg/kg intravenously every 3 weeks as a 21-day cycle
Continue until the disease is progressed

pembrolizumab / Berahyaluronidase

HER2-positive Administer dose of 790 mg/9600 units through subcutaneous route every six weeks Give prior to trastuzumab and chemotherapy when administered on the same day

Future Trends